Lyell Immunopharma, Inc. (NASDAQ:LYEL) CEO Lynn Seely Acquires 175,000 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CEO Lynn Seely acquired 175,000 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was bought at an average price of $0.61 per share, with a total value of $106,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 712,500 shares in the company, valued at approximately $434,625. This represents a 32.56 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Lyell Immunopharma Stock Down 6.5 %

Shares of NASDAQ:LYEL traded down $0.03 during trading on Tuesday, hitting $0.48. The stock had a trading volume of 1,199,720 shares, compared to its average volume of 1,041,784. The company has a market capitalization of $142.80 million, a PE ratio of -0.61 and a beta of -0.41. The firm’s fifty day moving average is $0.62 and its 200 day moving average is $0.90. Lyell Immunopharma, Inc. has a 12 month low of $0.48 and a 12 month high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The firm had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. Equities research analysts expect that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating and set a $1.00 price target on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP grew its holdings in Lyell Immunopharma by 1,285.5% in the third quarter. GSA Capital Partners LLP now owns 354,815 shares of the company’s stock worth $490,000 after purchasing an additional 329,205 shares during the period. Intech Investment Management LLC purchased a new position in shares of Lyell Immunopharma during the third quarter valued at approximately $52,000. Erste Asset Management GmbH bought a new stake in shares of Lyell Immunopharma in the 3rd quarter worth approximately $82,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Lyell Immunopharma in the 3rd quarter worth approximately $52,000. Finally, Centiva Capital LP bought a new position in Lyell Immunopharma during the 3rd quarter valued at approximately $31,000. 66.05% of the stock is currently owned by institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.